CXCL9



CXCL9

T1TT1L2LL2V3VV3I4II4R5RR5N6NN6A7AA7R8RR8C9CC9S10SS10C11CC11I12II12S13SS13T14TT14S15SS15R16RR16G17GG17T18TT18I19II19H20HH20Y21YY21K22KK22S23SS23L24LL24K25KK25D26DD26L27LL27K28KK28Q29QQ29F30FF30A31AA31P32PP32S33SS33P34PP34N35NN35C36CC36N37NN37K38KK38T39TT39E40EE40I41II41I42II42A43AA43T44TT44L45LL45K46KK46N47NN47... and 58 more residue(s)...... and 58 more residue(s)

SMILES None
InChIKey None
Sequence TLVIRNARCSCISTSRGTIHYKSLKDLKQFAPSPNCNKTEIIATLKNGDQTCLDPDSANVKKLMKEWEKKINQKKKQKRGKKHQKNMKNRKPKTPQSRRRSRKTT

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections


No bioactivity data available.

CXCL9

T1TT1L2LL2V3VV3I4II4R5RR5N6NN6A7AA7R8RR8C9CC9S10SS10C11CC11I12II12S13SS13T14TT14S15SS15R16RR16G17GG17T18TT18I19II19H20HH20Y21YY21K22KK22S23SS23L24LL24K25KK25D26DD26L27LL27K28KK28Q29QQ29F30FF30A31AA31P32PP32S33SS33P34PP34N35NN35C36CC36N37NN37K38KK38T39TT39E40EE40I41II41I42II42A43AA43T44TT44L45LL45K46KK46N47NN47... and 58 more residue(s)...... and 58 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections


Compound is not listed as a drug.